Growing evidence supports a role of host immune surveillance in influencing response to therapy and prognosis in HER2+ and triple-negative breast cancer, but not in HR-positive breast cancer which appears to be less immunogenic than HER2+ and triple-negative breast cancer [7]. This evidence concerns the gene ERBB2 and breast cancer.